Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer’s and Parkinson’s disease. The drug can be administered orally or in transdermal patches form, owing to its small molecular size.
Rivastigmine Market – Dynamics Increasing geriatric population is a major driver for growth of the rivastigmine market. According to The Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold above the age of 65 years in every 5 years. Moreover, increasing prevalence of cardiovascular diseases worldwide also accounts for the development of Alzheimer’s disease, thereby boosting demand for rivastigmine. As per the National Center for Biotechnology Information published in 2013, the incidence of cardiovascular diseases was around 22.5 per 1,000 person worldwide which in turn suggesting a risk of dementia.Diseases such as diabetes and blood pressure can also increase the risk of dementia, which further boosts demand for rivastigmine, thereby propelling the market growth. Request For Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/2407 Rivastigmine Market – Regional Insights The rivastigmine market is segregated geographically into North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America accounted for the largest share in the global rivastigmine market in 2017. This is owing to increasing prevalence of chronic kidney disease in the region that may lead to dementia. According to The American Kidney Fund, around 31 million people suffered from chronic kidney disease in 2015. Europe accounted for the second largest share in terms of revenue in the global rivastigmine market, in 2017 owing to increasing geriatric population in the region. Geriatric population is more prone to dementia. According to World Population Prospects (WPP), in 2017, around 25% of the population in Europe was aged 60 years or above. According to the Alzheimer’s Association, in 2017, there was significant prevalence of vascular diseases in Latin America and Africa. Therefore, Latin America and Africa are expected to witness significant growth in the global rivastigmine market during the forecast period. Rivastigmine Market – Competitive Landscape Major players operating in the global rivastigmine market include, Novartis Europharm Limited, Actavis Pharma, Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd, Dr. Reddy’s Laboratories, Macleods, and others. Key players in the market are focused on product development and approvals in order to enhance their market share. For instance, in 2007, U.S. FDA approved Exelon (Rivastigmine tartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's and Parkinson's disease. Global Rivastigmine Market Taxonomy: On the basis of disease indication, the global rivastigmine market is segmented into:
On the basis of formulation, the global rivastigmine market is segmented into:
Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/rivastigmine-market-2407 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 Comments
Hyperspectral imaging (imaging spectroscopy) systems are the result of extensive research and activity efforts. These systems have various applications in sectors such as healthcare, research and development, food industry, defense sector and others such as remote sensing, calorimetry and night vision. Hyperspectral imaging differs from multispectral imaging based on quality of image and provides greater sensitivity than conventional or multispectral imaging. For instance, multispectral imaging provides 2 to 20 images per dataset, while hyperspectral imaging provides over 20 images per dataset. Also, multispectral imaging gives 4 to 20 data points per pixel, while hyperspectral imaging provides full spectrum per pixel.
Request For Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/240 Increasing deployment of hyperspectral imaging in healthcare sector creates a highly conducive environment for growth of the hyperspectral imaging market in the near future. Hyperspectral imaging finds wide application in medical imaging, ophthalmology, and is also used in the procedures of gastrointestinal tract, in vascular systems and in tissue diagnosis. It is also an integral part of wound analysis, cell biology, and fluorescence microscopy. Wide application of the technology is mainly attributed to its high accuracy and clarity. Increasing adoption in pharmaceuticals sector fueling growth of the hyperspectral imaging market, especially in emerging economies The global hyperspectral imaging systems market globe is expected to witness double digit growth in the near future. In healthcare sector, these systems are used to perform various procedures in the pharmaceuticals industry. These include systems used to perform quality control tests that help detect foreign material present in drugs, and also mixed chemicals in counterfeit drugs. Also, hyperspectral imaging systems help in identification of targeted tumor tissue, a blood vessel, lymph nodes, a nerve bundle by covering the surface area of target and providing the image, in which that pixels of the image contains information regarding various light wavelength bands. Also, hyperspectral imaging finds extensive application in cancer treatment, as these systems provide real-time data and help in understanding the changes of tissue, which occur in the early stages of development of disease, also it helps to differentiate healthy cells from cancerous cells. Key Companies - Hyperspectral Imaging Market Some are the key companies providing innovative products in this area are, Headwall Photonics, HyperMed Imaging, Inc, Spectral Imaging Ltd., imec, Norsk Elektro Optikk AS (NEO), SpekLED GmbH and Resonon. Hyperspectral imaging market taxonomy: Global Market by Product Type: • Hyperspectral Imaging Cameras • Other accessories Global Market by Application: • Diagnostic Imaging • Biological (Wound Analysis, cell biology and fluorescence microscopy) • Ophthalmology • Pharmaceutical (Drug quality analysis) • Surgery Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/hyperspectral-imaging-market-240 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Seizures are further classified into mild seizures and stronger seizures depending on the severity of the seizures. The diagnosis of mild seizures are difficult, as its lasts only for few seconds. Stronger seizures may last for a few seconds to several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Epilepsy occurring due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
Request For Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1701 Antiepileptic Drugs Market Drivers Factors such as rising prevalence of epilepsy and robust pipeline are expected to boost the market growth over the forecast period. According to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally have epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China. Moreover, according to the Centers for Disease Control and Prevention, in 2017, an estimated 3.4 million people have active epilepsy in the U.S., which includes 3 million adults and 470,000 children. Manufacturers have potential drug molecules in the pipeline for the treatment of various forms of epilepsy. For instance, SK Life Sciences, Inc. has Cenobamate (YKP3089) in Phase 3 clinical trials. Eisai, Co., Ltd. has the drug Perampanel in Phase 2 clinical trials, and Marinus Pharmaceuticals, Inc. has the drug Ganaxolone in Phase II clinical trials. The expected launches of these drugs over the forecast period is expected to create favorable condition for the market growth. Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast period, owing to drug launches by leading manufacturers in the region. For instance, UCB Pharma received approval in Japan for Vimpat adjunctive therapy for partial onset seizures of epilepsy in 2016. Moreover, Eisai Pharma launched antiepilepsy drug Fycompa in India in 2017. Antiepileptic Drugs Market Competitive Landscape Key players operating in the global antiepileptic drugs market include GlaxoSmithKline plc, Johnson & Johnson, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, Cephalon, Inc., Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Novartis AG, UCB Pharma Ltd., and Sanofi S.A. Antiepileptic Drugs Market Taxonomy The global antiepileptic drugs market is segmented on the basis of drug class, distribution channel, and region: By Drug Class
Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/antiepileptic-drugs-market-1701 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Migraine is a neurological disorder that causes severe pain in head and results in nausea, vomiting, and extreme sensitivity to light and sound. The common types of migraine are with aura and without aura that means classical migraines and common migraines. Women are more prone to this disease than men. Therapeutic agents such as anti-inflammatory drugs (NSAIDs), for example aspirin, ibuprofen, sumatriptan, zolmitriptan, naproxen, anti sickness medicines and many more drugs are used to cure or lower the migraine. The symptoms of migraine can begin in childhood or in adulthood and it may progress through four stages such as prodrome, aura, headache and postdrome. Whereas aura occurs before or during a migraine, it is a symptom of nervous system that usually leads to visual disturbance such as flashes of light or zigzag vision. In this visual disturbance, around 20 to 60 minutes of vision loss occurs, also the pins, needles sensation in arms can be felt. Furthermore, it may lead to difficulty in speaking and can cause for uncontrollable movements of body.
The factors that trigger migraines include hormonal changes in female body, salty food and processed food, alcohol drinks, medications such as oral contraceptive and vasodilators for example nitroglycerin can cause migraines. Latest technology such as a new, smartphone controlled wireless patch has been devised that uses electrical stimulation to reduce the pain of migraines is going to be a revolutionary for migraine patients, Emerging drugs expected to boost the growth of migraine drugs market in the near future The launch of new drugs in market is expected to boost the margarine drugs market in the forecast period. For example, the Indian pharmaceutical company Cadila Healthcare Ltd. (Zydus Cadila) received the final approval on June 20, 2017, from the Food and Drug Administration (FDA) to market Eletriptan Hydrobromide tablets (20 mg and 40 mg), which is used in the treatment of migraine. Furthermore, another Indian pharmaceutical company Novartis has filed its migraine drug erenumab with the European Medicines Agency (EMA) on June 21, 2017. Which is expected to put other pharmaceutical companies into racing to develop a new drug for the treatment of migraine. Teva Pharmaceuticals Industries Ltd. an Israeli multinational pharmaceutical company which expected to file approval for fremanezumab (TEV-48125) drug by Food and Drug Administration (FDA) later this year (2017). This drug will be used in chronic migraine and the episodic migraine treatment, and this drug is expected to commercialize in market by the second half of 2018. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/575 Migraine disorders are among the most common disorders of the nervous system, it has been almost seen in adult population. Furthermore, North America holds the largest share in the migraine drug market as it holds a large number of ageing population, according to the U.S. Census Bureau in 2013 the aging population was around 14.1%As per World Health Organization (WHO) in 2016, globally it has been estimated that 50% of migraine disorders was found and percentage of this disorders is found high in women due to the hormonal influences. Also, according to the National Headache Foundation (NHF), people from the U.S. spend more than US$ 4 billion annually on drugs in the treatment of migraine pain. The factors influencing for migraine drugs market include increase in awareness about migraine treatment drugs and advancement in technology in the development of migraine drugs. According to the Migraine Research Foundation (MRF), migraine is a common neurological disease, around 38 million population including men, women and children in the U.S and 1 billion population around the globe is affected by it as of 2017. Excessive consumption of alcohol and increase in consumption of oral contraceptives significantly increases number of migraine disorder cases. Migraine Drugs Market Key Players Includes: The increased focus on drug development expected to support the market expansion of migraine drugs market players. There are various players across the globe running into the competition includes Endo International plc, Pfizer Inc., Aegis Therapeutics, LLC., Aeriel BioPharma, Alder BioPharmaceuticals Inc., Amgen Inc., Astellas Pharma Inc., CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., IntelGenx Corp., Johnson & Johnson, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Teva Pharmaceutical Industries LTD., Valeant Pharmaceuticals International, Inc., WINSTON PHARMACEUTICALS, Inc., Zogenix Inc., Abbott Laboratories, AstraZeneca plc, and GlaxoSmithKline plc. Click To Reading More On Migraine Drugs Market About Coherent Market Insights: Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected] https://www.coherentmarketinsights.com/phase-xs/ Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] The global reprocessed medical devices market was valued at US$ 1,054.6 million in 2016 and is expected to witness a robust CAGR of 20.4% during the forecast period (2017 – 2025).
Reprocessed medical devices are used to perform certain validated processes such as disinfection and sterilization that cab be further utilized again. Reprocessing involves three steps that are point of use processing, thorough cleaning and disinfection or sterilization. Post application of the three steps the devices are tested and remanufactured after appropriate packaging and labelling. Furthermore, such devices usually cost a significantly less as compared to the new device and thus, are widely preferred in cost-sensitive and emerging economies such as India and ASEAN countries. According to the Association of Medical Device Re-processors (AMDR), around 2 million tons of waste is generated by the U.S. hospitals each year and millions of waste include functional medical devices that are disposable in nature causes huge medical waste, which is the major source of carcinogens and further negatively affects the environment. In 2011, as per the United States International Trade Commission (USITC), the U.S is the largest consumer and manufacturer of medical devices and accounts for more than 35.0% of the global market. In the U.S., Original equipment manufacturers (OEMs) holds major share in sales of reprocessed medical devices market. This is mainly attributed to their robust sales and distribution network. Furthermore, as per the USITC some foreign countries such as the U.S., Canada account for a significant percentage of their sales. For instance, according to Remanufacturing Industries Council, the medical device market in countries such as Italy, India, Brazil, South Korea, Japan, Spain, and Portugal is accounted for 45% of GE Healthcare’s sales of reprocessed medical devices in 2011. Also, for the U.S., European countries are the major suppliers for reprocessed devices, followed by Canada and Mexico. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/234 The USITC statistics indicate that the production of reprocessed devices increased by 12% during 2009-2011. This is mainly attributed to production capacity expansion by a large number of medical device remanufacturers during this period. The 2008-2009 recession was the supportive factor behind this growth, as during this period various patients lost their medical insurance and it affected the reimbursement of devices, which in turn led to uptake of cost-effective devices. The cardiovascular medical devices segment is expected to retain its dominance over the forecast period, owing to reduction in product prize, increasing pressure to reduce expenditure of healthcare among hospital authorities, and increasing focus on protection of environment by reducing medical waste dumping. Increased focus on protecting the environment by reducing medical waste being dumped in landfills is significantly contributing to the growth for reprocessed medical devices market Over 90% of potentially infectious medical waste was incinerated before 1997. In August 1997, the U.S. Environmental Protection Agency (EPA) promulgated regulations creating stringent emission standards for medical waste incinerators due to significant concerns over detrimental air quality affecting human health. EPA’s Office of Air Quality Planning and Standards continues to review and revise the Hospital Medical Infectious Waste Incinerator (HMIWI) standards as required most recently in May of 2013. The growth in reprocessed medical devices market is also favored by the rise in awareness regarding the adverse environmental effects of dumping medical wastes in landfills. The widespread use of plastics and other non-biodegradable artificial polymers in medical devices is likely to magnify the benefit of this factor to the global reprocessed medical devices market, as the use of biodegradable materials in medical devices has still not been widely incorporated. According to World Health Organization (WHO), every year an estimated 16 billion injections are administered worldwide, but not all of the needles and syringes are properly disposed of afterwards. Some major key players in the global reprocessed medical devices market include Stryker Corporation, Johnson & Johnson, Vanguard AG), Medline ReNewal , SteriPro Canada, Inc., Pioneer Medical Devices AG, Vascular Solutions, Inc., HYGIA Health Services, Inc., ReNu Medical, Inc., SureTek Medical, Centurion Medical Products Corporation and Vanguard AG. Click To Reading More On Reprocessed Medical Devices Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] 3/28/2019 Attention-deficit/Hyperactivity Disorder (ADHD) Treatment Market Outlook Till 2026Read Now Attention deficit hyperactivity disorder (ADHD) is a neural disorder. The disorder is characterized by impulsiveness, hyperactivity, and attention difficulty. Treatment of ADHD involves a combination of counseling, medications, and lifestyle changes. ADHD is the most commonly diagnosed mental disorder in adults and children with the exact cause being unidentified in the majority of cases. Researchers at the National Institute of Mental Health (NIMH) suggest the factors affecting mental illness include heredity, brain injuries, low birth weight, drugs use during pregnancy and exposure to environmental toxins such, as lead at young age. The currently available treatments, such as medication, counseling, lifestyle changes or a combination of these treatments helps in reducing symptoms with improved functioning of patient.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/830 Rising number of drug-treated patients for ADHD therapy is expected to drive the attention deficit hyperactivity disorder (ADHD) treatment market According to the National Institute of Health estimates in 2015, the prevalence of ADHD is higher by 30% in boys, with 5.1 million children being diagnosed with ADHD globally in 2013 and the number expected to rise to 18 million by 2020. Increasing awareness of ADHD symptoms among patients and physicians, opinion-based diagnosis owing to the absence of standard diagnostic tests is expected to boost the revenue growth of ADHD therapeutics market in the forecast period. Additionally, rise in the ADHD therapeutics market is driven by increasing use of additives and preservatives in diet, value systems impacting quality of births, and changing lifestyles. However, restricted availability of non-stimulants ADHD drugs and existence of multiple conditions like schizophrenia or depression in children leads to underdiagnoses of ADHD in various geographies including Middle East and Africa, thereby restraining the growth of the market over the forecast period. Since Adderall abuse has grown to epidemic levels, our research team has compiled an article about the best all-natural alternatives to Adderall. Drug development and market consolidation strategies fuel the demand of some manufacturers Key players operating the attention deficit hyperactivity disorder (ADHD) treatment market include Eli Lilly, GlaxoSmithKline PLC, Pfizer Inc, Novartis AG and Shire PLC. The key strategies adopted by the manufacturers are developing cost-efficient drugs, which are safe for consumption and market consolidations. The other key vendors include Impax Laboratories, Hisamitsu Pharmaceutical Inc., Mallinckrodt Pharmaceuticals Inc., UCB S.A., Purdue Parma L.P and Johnson & Johnson. The non-stimulants market segment accounts for highest revenue share owing to its efficient treatment improving focus and impulsivity The global attention deficit hyperactivity disorder (ADHD) treatment market is segmented on the basis of drug type, distribution channel and geography. On the basis of drug type, the global attention deficit hyperactivity disorder (ADHD) treatment market is segmented into: • Stimulants o Amphetamine o Methylphenidate o Dexmethylphenidate o Dextroamphetamine o Lisdexamfetamine Dimesylate • Non-stimulants o Atomoxetine o Clonidine o Guanfacine o Bupropion On the basis of therapy, the global attention deficit hyperactivity disorder (ADHD) treatment market is segmented into: • Behavior Therapy • Cognitive Behavioral Therapy • Interpersonal Psychotherapy • Family Therapy Browse Full Exclusive Research Report at https://www.coherentmarketinsights.com/ongoing-insight/attention-deficit-hyperactivity-disorder-treatment-market-830 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] 3/28/2019 Neurorehabilitation Devices Market Increasing Emphasis to Promote Growth Till 2026Read Now Neurorehabilitation is a well-elaborated therapist-supervised medical procedure, which aims at recovering a nervous system injury resulting from non-functional to functional nervous system and improving the well-being of a person. World health organization (WHO) survey of 2014, revealed that each year around 15 million people are affected by neurological disorders, from which around 5 million suffer from permanent disability. The report also revealed that, around 2.5 million people are affected with multiple sclerosis and 10 million with Parkinson’s disease, every year, throughout the world. Increase in the prevalence of neurological diseases among the populace, creates a huge need to introduce neurorehab centers and neurorehabilitation devices to ensure simplification of normal-routine life and decrease patients’ dependability on others.
Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/740 Increase in opportunities and demand for neurorehabilitation devices in the market research industry Higher incidences of neurological disorders has helped boost the demand for neurorehabilitation devices over the recent years. People’s awareness related to health and the increasing investment in healthcare industry have created a high demand for these devices. According to Centers for Disease Control and Prevention (CDCP) 2015, around 130,000 individuals face fatal strokes every year in the United States. Thus, the increasing need to reduce the incidences of strokes every year, has resulted in the increasing demand for neurorehabilitation devices. Large number of people who are affected by Parkinson’s disease are recorded in regions such as U.S., U.K., Finland, Iceland, and Ireland. These regions extensively employ neurorehabilitation devices, fueling market growth. Additionally, age plays a critical role in increasing the risk of neurological related disease. Thus, regions with higher geriatric populations lend immense opportunities for growth of the neurorehabilitation devices market. Neurorehabilitation devices such as wearable technology, nanotechnology, and robotics, primarily work towards improving the nervous system, in turn reducing disability and increasing ease of daily functioning of individuals. Collaboration of key players to make lucrative developments The major key players of neurorehabilitation devices market are Bioness, Inc., Ectron Ltd., Hocoma AG, Medtronic, Tyromotion, Agiliad, Bioxtreme Robotics Rehabilitation, St Jude Medical Inc., Alter G Inc., Denecor, Ekso Bionics Holding Inc., Helius, Interactive Motion Technologies, Kinestica, Kinetic Muscles, Medtronic Plc., and Neurostyle. The neurorehabilitation devices market has been segmented on the basis of products, indication, and geography: On the basis of products, the neurorehabilitation devices market is segmented into: • Wearable Devices • Brain computer Interface • Neurorobotic System • Non-invasive Stimulators On the basis of indication, the neurorehabilitation devices market is segmented into: • Parkinson’s Disease • Stroke • Traumatic Brain Injury • Cerebral Palsy On the basis of region, the neurorehabilitation devices market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Browse In-Depth Analysis Research Report at https://www.coherentmarketinsights.com/ongoing-insight/neurorehabilitation-devices-market-740 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Immunoproteins refers to blood proteins that are involved in playing a role in the functioning of the immune system. These proteins possess an immunological activity against pathogenic organisms and substances as they display an abnormal increase in blood concentration thereby acting as a potential indicator in disease diagnosis during an unhealthy state. The immunoproteins form an integrated body system in cells, tissues or organs that helps to neutralize the harmful effects of antigens. The immunoproteins also helps in the diagnosis of several diseases that includes infectious diseases, cardiovascular diseases and oncological conditions.
High prevalence rates of chronic diseases to push the sales of the global immunoprotein diagnostic testing market The prime reason for growth in the demand for immunoprotein diagnostic testing services is the increase in prevalence and incidence rate of chronic diseases. According to WHO, the Global Health Observatory (GHO) data suggests that around 1.6 million which accounts up to 2.8% of the total deaths are caused due to diabetes. Moreover, the 2012, lung cancer alone was responsible to cause about 1.6 million deaths according to the statistics mentioned in the WHO report. To prevent such high mortality rates due to chronic disorders demands early diagnosis and suitable diagnostic testing. This is where the global immunoprotein diagnostic testing can serve a massive population thereby fueling its own growth at global level. Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/502 Increase in geriatric population coupled with high prevalence of non- communicable diseases responsibe to propel the global immunoprotein diagnostic testing market The major factors responsible to drive the global immunoprotein diagnostic testing market are the rise in geriatric population and the high prevalence and incidence rates of chronic diseases. According to WHO, the number of people suffering from Diabetes has risen from 108 million in 1980 to 422 million in 2014, suggesting rapid rise in the prevalence and incidence of diabetes. Moreover, according to Global Health Observatory data published by WHO in 2017, around 70% of global deaths accounting up to 39.5 million are caused due to non- communicable diseases (NCD) such as cardiovascular diseases, chronic lung diseases, cancers and diabetes. Top Key Players : The key players dominating the global immunoprotein diagnostic testing market includes Abbott Laboratories, Inc., Abcam PLC, Agilent Technologies, AdnaGen, BioMerieux, Enzo Life Sciences, Inc., Fujirebio Diagnostics, Inc., DiaSorin SPA, Roche, Randox Laboratories and Thermo Fisher Scientific. These companies are able to hold their position in the global immunoprotein diagnostic testing market due to consequent advancement in technological aspects. For instance, increasing sensitivity and ease of use while performing ELISA to develop radioimmunoassay keeping in mind the cost effective terms so as to make it accessible and affordable to a population that is price- sensitive. The chemiluminescent segment exhibits a rapid growth in the global immunoprotein diagnostic testing that can be attributed to the wide scope of application and ease of use The global immunoprotein diagnostic testing market is segmented on the basis of technology, test type, application and geographical regions. On the basis of Technology, • Radioimmunoassay • Immunoturbidity Assay • Chemiluminescence Assay • Immunoprotein Electrophoresis • Enzyme- based Immunoassay • Immunofluorescence Assay On the basis of Test Type, • C- reactive Protein Diagnostic Test • Complement System Protein Diagnostic Test • Prealbumin Diagnostic Test • Hepatoglobin Diagnostic Test • Immunoglobulin Diagnostic Test • Free Light Chain Diagnostic Test • Others Request For Customization of This Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/502 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] 3/27/2019 Smart Home Medical Device Market Research, Analysis and Forecasted Healthcare IndustryRead NowPost-discharge care plays an extremely important role in ensuring speedy and effective recovery of the patient. This is especially a matter of concern for the elderly as well as pediatric population who mostly spend their time at home and are usually dependent on someone else to ensure continued care. However, due to busy lifestyle of the populace in developed and emerging economies, post-discharge care is often hampered. This concern of family members as elderly people living alone is expected to favor growth of the market for smart home medical devices, such as fall detection system, bathroom sensors, monitoring and detecting systems and assisting systems. According to a Welfare Ministry Survey, in 2016, there were around 6.24 million people aged 65 and above were living alone in Japan. The increasing lonely deaths in the region is also a vital factor that is expected to favor the smart home medical device market.
Growing internet penetration favors growth of smart home medical devices market: Smart home medical device is latest and futuristic approach towards making life easier and secure. This revolutionary step by the medical devices company has affected the healthcare industry and the adoption rate for such technology in a positive way. While most consumers and healthcare organizations were skeptical about the technology, the scenario is rapidly changing, with higher adoption rate of such devices, a trend that is expected to continue over the forecast period. Furthermore, the wide availability of the smart home medical devices is a crucial block to fill the loop hole for acceptance of such devices and services. Easily available personal monitoring system and other electronic devices are expected to favor rise in adoption of smart home medical devices. Smart home basically defined as the residence that uses controllers to integrate the functions of the device installed at home. The controllers are connected through a computer that is connected via internet and the data of the respondent is recorded on cloud or on-premises data bank, which can be further monitored by the physician or caretaker accordingly. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/111 Growth in adoption of health caregiving is expected to underpin the smart home medical device market According to American Association of Retired Persons (AARP), in 2016, around 80% growth has been observed in the medication management segment in the health caregiving market, which in turn is expected to support growth of the smart home medical device market in the near future. Medical technology utilized in home care settings, where the caregivers are active, ranges between complex and simple materials that are also used for administering first aid to sophisticated devices and advanced medical treatment. The products involved in home care settings can vary from tiny wireless devices to massive machines. Smart home medical devices such as blood pressure measuring equipment, sugar level measuring equipment and devices are widely used. Highly fragmented market due to dominance of ICT organizations in smart home medical device manufacturing The global smart home medical device market is highly fragmented market as encompasses pharmaceuticals, healthcare and information and communication technology industries. Growth in internet of things segment and its acceptance globally is expected to support the market for smart home medical device. Although, it is a difficult task to align the technology to the human vitals, incorporating the appropriate features into a medical device that are utilized by the patient or the care recipient at home is the most challenging factors for such devices. Major players involved in the smart home medical device market include ViVO Smart Medical Devices Ltd., Health Care Originals, Hocoma AG, VitalConnect, Proteus Digital Health, Cyrcadia Health, Qardio, Inc., and Neurometrix. Click To Reading More On Smart Home Medical Device Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] |
Details
Global Industry Research Experienced Professional Freelancer with a demonstrated history of working in the information technology and services industry. Skilled in Front Office, Customer Service, Marketing, Microsoft Office, and Social Media. Strong media and communication professional with a Bachelor of Commerce - BCom focused in Computer and Information Sciences and Support Services from Pune University. Archives
July 2020
Categories |